Opinion &amp; analysis

OTC Marketing Awards 2019 Winners Announced – GSK Crowned Company Of The Year, Pfizer’s Viagra Takes Best Brand

Find out who the big winners were at the 24th annual OTC Marketing Awards. This article contains highlights from the gala awards evening, as well as a full list of all winners announced at the event, which celebrates the best in the British OTC industry.

March 8, 2019

Real-World Evidence Takes Courage: A Conversation With IQVIA’s Nancy Dreyer

The 21st Century Cures Act’s call for the use of real-world evidence (RWE) is slowly moving toward reality. But hurdles abound, warns IQVIA’s Nancy Dreyer. For instance, the FDA–which is behind the EMA in this area–appears split. Privacy concerns and lack of interoperability hinder progress. Learn why this sometimes-muddied distinction between randomized clinical trial data and RWE is so important, and find out RWE’s role in label expansions.

February 11, 2019

The Advantages Of Providing Access To Unlicensed Medicines

As pharma companies increasingly include access to unlicensed medicines as part of their commercialization game plans, new challenges – and opportunities – are born. In this informative article, In Vivo examines both the potential pitfalls and probable triumphs of incorporating unlicensed medicines into commercial strategies.

November 5, 2018

CEO-To-Worker Pay Ratios Averaged 150-1 At Six Top Medtech Companies In 2017

CEOs earned 32- to 215- times that of the median worker at six device companies. Find out which CEO earned $10.8 billion–215 times the median salary–and see how company revenues compare to the CEO/worker pay ratio. The average ratio for the six firms is 150-1: Discover how this compares to other public companies across industries.

April 9, 2018

Roche: We’ve Abandoned Budgets And It’s Liberated Employees

Imagine what would happen if a huge corporation abandoned the core competency of controlling its multi-million-dollar budgets and accelerating processes across R&D and commercial divisions. Would it survive? Would it actually thrive? Scrip talks to one CEO who knows.

August 2, 2019

Focus More On Patients, Less On Hospitals, Experts Tell Device Companies

Several medtech industry experts sat down with Medtech Insight to share their views on how the medical devices industry can remain competitive in a shifting healthcare climate by moving its focus to serving patients, rather than catering to doctors and hospitals.

November 1, 2018

GSK Woes Raise Big Pharma R&D Question

Should big pharma still do in-house discovery and early development? Maybe not; GSK’s unsuccessful efforts to boost productivity suggest it’s impossible for big pharma to re-create biotech-like innovation internally. Learn why big pharma should stick to late-stage development and how it can maintain its competitive advantage.

December 4, 2017

FDA’s Quality System Regulation Is Mapped To International Standard ISO 13485 – And Vice Versa – In New Report From AAMI

A new Technical Information Report from the Association for the Advancement of Medical Instrumentation aims to help befuddled US device makers that operate under the FDA’s QSR ensure they are compliant with standard from the ISO.

August 2, 2019

Lilly Prices Olumiant For JAK Battle, But Misses Approval For Higher Dose

How do you compete with rheumatoid arthritis giants Humira and Xeljanz? Eli Lily & Co. is betting that pricing their janus kinase (JAK) inhibitor, Olumiant at 50% and 60% less, respectively, may just do the trick. Find out more about Lily’s gambit, even as Olumiant failed to gain FDA approval for a 4mg dose.

June 2, 2018

GSK And Pfizer Assemble Consumer Healthcare Leadership Team As JV Closes

GlaxoSmithKline PLC and Pfizer Inc. have closed their consumer health joint venture to create the “global leader in OTC products.” Operating under the GSK Consumer Healthcare name, the joint venture – announced in December last year – has around a 7.3% share of the global consumer health market, well ahead of the next competitor, Johnson & Johnson, at 4.1%. Under the leadership of Brian McNamara, the new company has begun to assemble a management team that combines talent from both GSK and Pfizer. Who’s on the dream team, and what’s on the horizon for this new superpower?

August 2, 2019

J.P. Morgan Notebook Day 2: Biogen, GSK, Bluebird, Roche, Amgen, Biohaven And Lilly

The second day of the 2019 JP Morgan Healthcare Conference has concluded, and Pink Sheet was there to bring you all of the breaking news, major announcements, and insights from the largest investment healthcare symposium in the world.

January 9, 2019

Roche’s External Control Arms Show What Real-World Evidence Can Look Like In Practice

Roche is leading the charge in the emerging field of using real-world evidence (RWE) with its recent acquisition of Flatiron Health, Inc. and Flatiron’s electronic health records database. Take a closer look at the use of RWE in actual practice in this illuminating article from Pink Sheet.

June 14, 2018

ECHA’s Microplastic Ban Proposal Is ‘Brutally Misinformed’ – Cosmetics Europe

ECHA’s plan to ban the use of intentionally added microplastics in cosmetics is based on “a whole clutch of errors and misunderstandings,” according to Cosmetics Europe’s Director-General John Chave. Find out why the industry is worried about this ban–and why they consider it unfair. Gain insights into which solutions would satisfy the industry, and learn why biodegradable plastics–which represent a potential win-win for industry and environmental advocates–may not be viable.

February 19, 2019